| CTC\_group | CTC\_grade | control | exercise |
| --- | --- | --- | --- |
| Renal and urinary disorders | 3 | 1 |  |
| Gastrointestinal disorders | 3 |  | 1 |
| Cardiac disorders | 2 | 1 |  |
| Gastrointestinal disorders | 2 | 1 |  |
| General disorders and administration site conditions | 2 |  | 1 |
| Infections and infestations | 2 |  | 1 |
| General disorders and administration site conditions | 1 | 2 | 4 |
| Infections and infestations | 1 | 2 | 1 |
| Metabolism and nutrition disorders | 1 | 1 |  |
| Musculoskeletal and connective tissue disorders | 1 | 2 | 3 |
| Nervous system disorders | 1 | 1 | 1 |
| Skin and subcutaneous tissue disorders | 1 | 1 | 1 |
| Gastrointestinal disorders | 1 |  | 1 |
| Respiratory, thoracic and mediastinal disorders | 1 |  | 3 |
| Social circumstances | 1 |  | 1 |
| Supplemental Figure - Total count of adverse events by randomization divided into CTC categories    This method only regards to AEs assessed at week 4, week 8 and followup | | | |